• Dyadic International Inc., of Jupiter, Fla., said its scientists would work with researchers at the new Scripps Research Institute facility in Palm Beach County, Fla., to provide a complete annotation of the genome of Dyadic's fungal organism, Chrysosporium lucknowense (C1), which was sequenced last year. Dyadic, an enzyme company, expects that to facilitate further development of its C1 Host Technology as a platform for the discovery, development and production of biotherapeutics, enzymes and other biomolecules for medical and industrial applications. Financial terms were not disclosed.

• Gen-Probe Inc., of San Diego, filed an amended biologics license application with the FDA for the Procleix Ultrio assay on the Procleix enhanced semi-automated system (eSAS). The amendment responds to agency questions in an October complete review letter on the assay, which was developed to simultaneously detect HIV-1, hepatitis C virus and hepatitis B virus in donated blood, plasma, organs and tissues. Separately, the company reiterated its intent to file for approval of the fully automated Procleix Tigris system to run a blood screening test for West Nile virus by the end of April.

• Interleukin Genetics Inc., of Waltham, Mass., named Kenneth Kornman CEO. Kornman is the founder, president and chief scientific officer of the company, and will continue to oversee the company's relationship with its partner, Alticor Inc., of Ada, Mich., to facilitate the launch of genetic tests globally. Interleukin also named Gregg Mayer chief business officer. Philip Reilly will continue as chairman, but stepped down as CEO.

• Peregrine Pharmaceuticals Inc., of Tustin, Calif., filed a shelf registration statement with the SEC that will allow the company to offer and sell up to 15 million shares of common stock from time to time. The company intends to use the proceeds to advance its clinical programs and for other general corporate purposes. It is pursuing three clinical trials in cancer and antiviral indications with its lead product candidates Tarvacin and Cotara.

• Quintiles Transnational Corp., of Research Triangle Park, N.C., completed new credit facility arrangements, which include a $225 million first lien revolving credit facility due in 2012, a $1 billion first lien term load due in 2013 and a $220 million second lien term loan due in 2014. Proceeds, along with available cash, were used to pay the purchase price for notes accepted in a tender offer and to cash out the outstanding preferred stock of Pharma Services Holding Inc., Quintiles' parent company, as part of the mergers of Pharma Services and Pharma Services Intermediate Holding Corp. into Quintiles.

• Serologicals Corp., of Atlanta, completed its acquisition of Cytomyx Ltd., a subsidiary of Cytomyx Holdings plc, of Cambridge, UK., which is a leading provider of ion channel cell lines and drug discovery services. Serologicals paid $7 million for the stock of Cytomyx.

• Vical Inc., of San Diego, said an influenza DNA vaccine formulated with its Vaxfectin adjuvant protected mice against lethal challenges with two different strains of human influenza virus. The vaccines targeted highly conserved flu proteins - nucleoprotein (NP) and matrix protein (M2) - and were systematically tested with Vaxfectin and other formulations, and Vaxfectin-formulated vaccines demonstrated statistically superior protection in mice, particularly at low doses, against lethal challenges with H1N1 or H3N2 strains of flu. The data were presented at the Keystone Symposium, "Advances in Influenza Research: From Birds to Bench to Bedside." On Friday, Vical's stock (NASDAQ:VICL) gained 79 cents, or 14.6 percent, to close at $6.18.

• VM Discovery Inc., of Fremont, Calif., and Fred Hutchinson Cancer Research Center entered a collaboration to jointly pursue a cancer drug discovery program. Under the terms, VMDI will use its multi-property drug design and optimization technology platform, the VM Optimzer, to generate and optimize small-molecule leads and clinical candidates. The Hutchinson Center will leverage its expertise in cancer biology and technologies. Specific terms were not disclosed.